Verrica Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Verrica Pharmaceuticals

14/05/2025 17:26

Verrica Pharmaceuticals Inc VRCA.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -44 cents.  The mean expectation of six analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -7 cents per share.

Revenue fell 10.6% to $3.42 million from a year ago; analysts expected $2.51 million.

Verrica Pharmaceuticals Inc's reported EPS for the quarter was a loss of 10 cents​.

The company reported a quarterly loss of $9.74 million.

Verrica Pharmaceuticals Inc shares had risen by 24.4% this quarter and lost 21.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.5% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "hold."

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $3.00

This summary was machine generated from LSEG data May 14 at 04:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.10
-0.10
Met
Dec. 31 2024
-0.26
-0.24
Beat
Sep. 30 2024
-0.37
-0.49
Missed
Jun. 30 2024
-0.42
-0.37
Beat